Compare Freshworks Inc (FRSH) vs Pfizer Inc (PFE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Freshworks Inc vs Pfizer Inc — how do they compare? Freshworks Inc trades at $13.75 (market cap $3.56B), while Pfizer Inc trades at $27.72 (market cap $158.56B). The key difference: Pfizer Inc is far larger — about 44.5× Freshworks Inc's market cap, and Pfizer Inc pays a 6.18% dividend while Freshworks Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Freshworks Inc for 39 Days and Pfizer Inc for 158 Days on average.
| FRSH | PFE | |
|---|---|---|
Market Cap | $3.56B | $158.56B |
Volume | 9,066,454 | 44,138,282 |
Sector | Technology | Health |
52-Week High | $13.92 | $29.02 |
52-Week Low | $6.88 | $23.67 |
Typical Hold Time | 39 Days | 158 Days |
Enterprise Value | $2.93B | $210.06B |
Dividend Yield | — | 6.18% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Freshworks (FRSH) trades at $13.60, down 1.16% on the day, with a bullish technical outlook from moving averages. The company reported strong Q2 2026 results, beating earnings estimates with EPS of $0.17 versus $0.13 expected, and achieved its first quarter of GAAP profitability. Revenue growth remains robust at 16% year-over-year, supported by strength in its employee experience portfolio and AI adoption.
The investment outlook is positive, driven by sustained revenue growth, improving profitability, and a favorable analyst consensus with a $14.60 price target. Key risks include high valuation multiples like a 43.89 EV/EBITDA and competitive pressures in the SaaS sector. The stock presents an opportunity for rerating if profitability trends continue.
Pfizer (PFE) trades at $28.00, up 1.87% on the day, with a bullish technical signal from moving averages. The company reported revenue of $62.58 billion in 2025 with a net income margin of 6.8%, and has beaten EPS estimates for the last three quarters. Recent news highlights Pfizer's focus on its obesity and oncology pipeline as key growth drivers in 2026.
The stock presents a value opportunity with a consensus price target of $29.17, but faces risks from patent expirations and projected earnings decline. Investor sentiment is mixed, with analysts largely neutral, emphasizing the stock's defensive cash flow and dividend yield amid ongoing business transformation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Freshworks Inc
Freshworks Inc provides software as a service platform that enables small and medium-sized businesses to support customers through e-mail, phone, website, and social networks. It offers solutions that serve the needs of users in the CX and ITSM categories, and have also expanded its offering with Sales and Marketing automation products. These product offerings enable organizations to acquire, engage, and better serve their customers and employees.
Read more on FRSH →About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →
